Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial.

Gómez-Medina AM, Henao-Carillo DC, Villamil-Castañeda LP, Gómez-Quesada Y, Muñoz-Velandia OM, Yepes CA, Chaim SN, Pertuz-Noriega CE, Aschner P

Diabetologia4 Aug 2025Cited by 1 (Europe PMC)

PMID40760249PMCIDPMC12361261DOI10.1007/s00125-025-06446-yPepBankPUB-40760249

Download PDF PubMedAsk about this study

Jump to 6 results

Summary

Aims/objectiveThe aim of the study was to assess the safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels <3.0 mmol/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up) for insulin degludec/liraglutide (IDegLira) compared with multiple daily insulin injections (MDI) during the transition from hospital to an outpatient setting.MethodsThe study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes. The study evaluated the percentage of patients with at least one hypoglycaemic event, the hypoglycaemia event density, the time in range (TIR 3.8-10 mmol/l), the time below range (TBR <3.0 or <3.8 mmol/l), and other glycaemic management metrics measured by continuous glucose monitoring.ResultsSixty-four patients were included in the analysis (32 in each group). They had a baseline HbA_1c of 103 ± 11.6 mmol/mol (11.6 ± 1.7%) and age of 58 ± 12.4 years (means ± SD). The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008). The TIR 3.8-10 mmol/l was higher in the IDegLira group (80.6% vs 69.7%; p=0.008). The findings were consistent regardless of baseline HbA_1c.Conclusions/interpretationIDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care.Trial registrationClinicaltrials.gov NCT05767255 FUNDING: This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE).

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In T2DM patients after hospital discharge, IDegLira reduced the proportion with a hypoglycaemic event lasting more than 15 min below 3.0 mmol/l during first 4-week follow-up versus MDI (6.2% vs 31.3%; p<0.010).
In plain wordsIn T2D patients after discharge, fewer people taking IDegLira had at least one low-blood-sugar event than with multiple daily insulin injections.
Peptide
Liraglutide
Outcome
Decreasepatients with hypoglycaemic event
Study
n = 64
Comparator
multiple daily insulin injections
Analysis
Primary
Outcome group
Adverse events · Metabolic and weight
Measurements
Patients with hypoglycaemic event
6.2%
IDegLira
Patients with hypoglycaemic event
31.3%
MDI
P-value
< 0.01
IDegLira versus MDI
Source sentences
Summary
The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008).
3 context sentences(design, population, supporting numbers)
Summary · context
safety profile (defined as the percentage of patients with at least one hypoglycaemic event [more than 15 min with glucose levels <3.0 mmol/l as documented by continuous glucose monitoring] in the first 4 weeks of follow-up
Summary · context
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes.
Summary · context
Sixty-four patients were included in the analysis (32 in each group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4076024901
02HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In T2DM patients after hospital discharge, hypoglycaemia event density was lower with IDegLira than MDI; the published IRR 15.2 (95% CI 6.2, 48.2; p<0.001) is retained without inversion.
In plain wordsIn T2D patients after discharge, IDegLira had fewer low-blood-sugar events than multiple daily insulin injections.
Peptide
Liraglutide
Outcome
Decreasehypoglycaemia event density
Study
n = 64
Comparator
multiple daily insulin injections
Outcome group
Adverse events · Metabolic and weight
Measurements
Published incidence rate ratio
15.2
orientation unstated; IDegLira-versus-MDI outcome
95% CI
6.2 to 48.2
published hypoglycaemia event-density interval
P-value
< 0.001
event-density contrast
Source sentences
Summary
The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes.
Summary · context
Sixty-four patients were included in the analysis (32 in each group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4076024902
03HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In patients with type 2 diabetes after hospital discharge, IDegLira reduced time below range below 3.8 mmol/l versus multiple daily insulin injections.
In plain wordsIn T2D patients after discharge, IDegLira spent less time below blood-sugar range than multiple daily insulin injections.
Peptide
Liraglutide
Outcome
Decreasetime below range below 3.8 mmol/l
Study
n = 64
Comparator
multiple daily insulin injections
Outcome group
Adverse events · Metabolic and weight
Measurements
TBR <3.8 mmol/l
0.9%
IDegLira
TBR <3.8 mmol/l
2.9%
MDI
P-value
0.019
TBR <3.8 mmol/l comparison
Source sentences
Summary
The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes.
Summary · context
Sixty-four patients were included in the analysis (32 in each group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4076024903
04HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In patients with type 2 diabetes after hospital discharge, IDegLira reduced time below range below 3.0 mmol/l versus multiple daily insulin injections.
In plain wordsIn T2D patients after discharge, IDegLira spent less time far below blood-sugar range than multiple daily insulin injections.
Peptide
Liraglutide
Outcome
Decreasetime below range below 3.0 mmol/l
Study
n = 64
Comparator
multiple daily insulin injections
Outcome group
Adverse events · Metabolic and weight
Measurements
TBR <3.0 mmol/l
0.6%
IDegLira
TBR <3.0 mmol/l
1.3%
MDI
P-value
0.008
TBR <3.0 mmol/l comparison
Source sentences
Summary
The proportion of patients with at least one hypoglycaemic event (plasma glucose <3.0 mmol/l) was lower in the IDegLira group than in the MDI group (6.2% vs 31.3%; p<0.010), as was the hypoglycaemia event density (incidence rate ratio 15.2; 95% CI 6.2, 48.2; p<0.001), TBR <3.8 mmol/l (0.9% vs 2.9%; p=0.019) and TBR <3.0 mmol/l (0.6% vs 1.3%, p=0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes.
Summary · context
Sixty-four patients were included in the analysis (32 in each group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4076024904
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes after hospital discharge, IDegLira increased time in range 3.8-10 mmol/l versus multiple daily insulin injections.
In plain wordsIn T2D patients after discharge, IDegLira increased time in target blood-sugar range versus multiple daily insulin injections.
Peptide
Liraglutide
Outcome
Increasetime in range 3.8-10 mmol/l
Study
n = 64
Comparator
multiple daily insulin injections
Outcome group
Glycemic control · Metabolic and weight
Measurements
TIR 3.8-10 mmol/l
80.6%
IDegLira
TIR 3.8-10 mmol/l
69.7%
MDI
P-value
0.008
TIR 3.8-10 mmol/l comparison
Source sentences
Summary
The TIR 3.8-10 mmol/l was higher in the IDegLira group (80.6% vs 69.7%; p=0.008).
2 context sentences(design, population, supporting numbers)
Summary · context
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes.
Summary · context
Sixty-four patients were included in the analysis (32 in each group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4076024905
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In T2DM patients after hospital discharge, findings for IDegLira versus MDI were consistent regardless of baseline HbA<sub>1c</sub>; stratum-specific estimates, tests and analyzed Ns were unstated.
In plain wordsIn T2D patients after discharge, IDegLira findings versus multiple daily insulin injections were consistent across baseline HbA1c; subgroup estimates were unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedTrial-result consistency across baseline HbA1c
Study
n: not reported in source
Comparator
multiple daily insulin injections
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The findings were consistent regardless of baseline HbA_1c.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was an open-label, randomised, controlled clinical trial comparing IDegLira to MDI after hospital discharge in patients with type 2 diabetes.
Summary · context
Sixty-four patients were included in the analysis (32 in each group).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4076024906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 3NCT05767255

Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue

Hospital Universitario San Ignacion = 661 Dec 2022 to est. 30 Aug 2023

Diabetes Mellitus, Type 2 Treated With Insulin

Trial page ClinicalTrials.govUpdated 14 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.